[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Kim OK, Kim SH, Kim JB, Jeon WS, Jo SH, Lee JH, Ko JH: Transluminal removal of a fractured and embolized indwelling central venous catheter in the pulmonary artery. Korean J Intern Med; 2006 Sep;21(3):187-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 39-year-old woman underwent placement of a totally implantable venous access device for chemotherapy to treat a recurrent liposarcoma of the left thigh.
  • [MeSH-minor] Adult. Female. Humans. Liposarcoma / drug therapy. Thigh / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Jan 15;61(2):376-8 [3334972.001]
  • [Cites] Radiology. 1990 Nov;177(2):353-6 [2217768.001]
  • [Cites] Can J Surg. 1991 Jun;34(3):278-81 [2054760.001]
  • [Cites] Eur J Surg. 1993 Jun-Jul;159(6-7):323-7 [8104491.001]
  • [Cites] J Vasc Interv Radiol. 1993 Nov-Dec;4(6):805-10 [8281004.001]
  • [Cites] Dtsch Med Wochenschr. 1996 Jan 19;121(3):47-51 [8565809.001]
  • [Cites] Am J Surg. 1984 Nov;148(5):633-6 [6496853.001]
  • [Cites] Eur J Surg Oncol. 1998 Jun;24(3):192-9 [9630859.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):767-73 [9739444.001]
  • [Cites] Vascular. 2005 Mar-Apr;13(2):120-3 [15996367.001]
  • [Cites] J Emerg Med. 2003 Jan;24(1):29-34 [12554037.001]
  • [Cites] Angiology. 2004 Sep-Oct;55(5):557-60 [15378119.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):222-5 [8667632.001]
  • (PMID = 17017669.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3890723
  •  go-up   go-down


2. Vallurupalli S, Huesmann G, Gregory J, Jakoby MG 4th: Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia. Diabet Med; 2008 Jul;25(7):856-9
Hazardous Substances Data Bank. Ofloxacin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 63-year-old man with Type 2 diabetes mellitus was admitted to hospital for resection of a large liposarcoma.
  • On days 6-8 of levofloxacin therapy, the patient experienced recurrent hypoglycaemia despite total parenteral nutrition, 10% dextrose containing fluids and cessation of insulin therapy 3 days prior to the first hypoglycaemic episode.
  • After a final and severe hypoglycaemic event, the patient developed quadriplegia and tonic left deviation of gaze.
  • [MeSH-minor] Diabetes Mellitus, Type 2 / complications. Diabetic Neuropathies / complications. Humans. Kidney Neoplasms / complications. Kidney Neoplasms / surgery. Liposarcoma / complications. Liposarcoma / surgery. Male. Middle Aged. Myelinolysis, Central Pontine / complications. Peritonitis / prevention & control. Postoperative Complications / prevention & control

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Levofloxacin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2007 Apr;117(4):910-8 [17404617.001]
  • [Cites] Intensive Care Med. 2000 Sep;26(9):1406-7 [11089780.001]
  • [Cites] Diabetes Care. 1984 Nov-Dec;7(6):613 [6391878.001]
  • [Cites] Stroke. 1992 Jan;23(1):112-3 [1731410.001]
  • [Cites] Stroke. 1993 Jan;24(1):143 [8418544.001]
  • [Cites] Brain Res. 1993 Mar 19;606(1):19-27 [8096428.001]
  • [Cites] Stroke. 1996 Sep;27(9):1648-55; discussion 1655-6 [8784143.001]
  • [Cites] Drug Saf. 1998 Feb;18(2):83-97 [9512916.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1352-61 [16510739.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11 [16410743.001]
  • [Cites] Neuroreport. 2006 Jan 23;17(1):55-9 [16361950.001]
  • [Cites] Pharmacotherapy. 2005 Oct;25(10):1303-9 [16185173.001]
  • [Cites] Pharmacotherapy. 2005 Oct;25(10):1296-302 [16185172.001]
  • [Cites] Gen Hosp Psychiatry. 2005 Sep-Oct;27(5):372-4 [16168799.001]
  • [Cites] Stroke. 2005 Mar;36(3):e20-2 [15692119.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1959 Feb;81(2):154-72 [13616772.001]
  • [Cites] Diabet Med. 1998 Mar;15(3):259-61 [9545129.001]
  • [Cites] Diabet Med. 2004 Jun;21(6):623-4 [15154950.001]
  • [Cites] Eur J Pharmacol. 2004 Aug 16;497(1):111-7 [15321742.001]
  • (PMID = 18644072.001).
  • [ISSN] 1464-5491
  • [Journal-full-title] Diabetic medicine : a journal of the British Diabetic Association
  • [ISO-abbreviation] Diabet. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 6GNT3Y5LMF / Levofloxacin; A4P49JAZ9H / Ofloxacin
  • [Other-IDs] NLM/ PMC2613252
  •  go-up   go-down


3. Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ, Ytterberg SR, Allen NB, Hoffman GS, Wegener's Granulomatosis Etanercept Trial Research Group: Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum; 2006 May;54(5):1608-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo-controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone.
  • This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients.
  • At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded.
  • The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastatic cholangiocarcinoma, renal cell carcinoma, and breast carcinoma, and 1 recurrent liposarcoma.
  • There were no differences between the 2 treatment groups in sex distribution, disease severity, personal or family history of cancer, or tobacco and alcohol use.
  • The etanercept group was older at baseline and less likely to be newly diagnosed with WG at the time of randomization.
  • Patients who developed solid tumors were older than patients who did not.
  • All etanercept-treated patients who developed solid tumors were also treated with cyclophosphamide during the trial.
  • There were also no differences in the mean duration of daily cyclophosphamide therapy or the maximum daily cyclophosphamide dosage before enrollment.
  • CONCLUSION: Data from the WGET, the first substantial reported experience of the combined use of etanercept and cyclophosphamide in the treatment of WG, indicate that the combination of TNF inhibition and cyclophosphamide may heighten the risk of cancer beyond that observed with cyclophosphamide alone.
  • [MeSH-major] Granulomatosis with Polyangiitis / drug therapy. Immunoglobulin G / adverse effects. Neoplasms / chemically induced. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16646004.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Grant] United States / FDA HHS / FD / FD-R-001652-01; United States / NIAMS NIH HHS / AR / K24-AR-02126-04; United States / NIAMS NIH HHS / AR / K24-AR-049185-01; United States / NIAMS NIH HHS / AR / K24-AR-2224-01A1; United States / NCRR NIH HHS / RR / M01-RR-30; United States / NCRR NIH HHS / RR / M01-RR0-0042; United States / NCRR NIH HHS / RR / M01-RR0-00533; United States / NCRR NIH HHS / RR / M01-RR0-2719; United States / NIAMS NIH HHS / AR / N01-AR-9-2240
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; OP401G7OJC / Etanercept
  •  go-up   go-down


Advertisement
4. Blay JY, von Mehren M, Samuels BL, Fanucchi MP, Ray-Coquard I, Buckley B, Gilles L, Lebedinsky C, Elsayed YA, Le Cesne A: Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res; 2008 Oct 15;14(20):6656-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
  • PURPOSE: To determine the dose of trabectedin plus doxorubicin with granulocyte colony-stimulating factor support associated with manageable neutropenia and acceptable dose-limiting toxicities (DLT) in patients with recurrent or persistent soft-tissue sarcoma.
  • METHODS: In this phase I, open-label, multicenter trial, patients previously treated with 0-1 prior chemotherapy regimens excluding doxorubicin, an Eastern Cooperative Oncology Group performance status 0-1, and adequate organ function received a 10- to 15-min i.v. infusion of doxorubicin 60 mg/m(2) immediately followed by a 3-h i.v. infusion of trabectedin 0.9 to 1.3 mg/m(2) on day 1 of a 3-week cycle.
  • RESULTS: Patients (N = 41) received a median of six cycles of treatment (range, 2-13).
  • Common grade 3/4 treatment-emergent adverse events were neutropenia (71%), alanine aminotransferase increase (46%), and thrombocytopenia (37%).
  • CONCLUSION: The combination of doxorubicin 60 mg/m(2) followed by trabectedin 1.1 mg/m(2) every 21 days is safe and active in patients with soft-tissue sarcoma.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5484-92 [16110008.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1867-74 [15774779.001]
  • [Cites] Cancer Radiother. 2006 Jun;10(4):185-207 [16917992.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):231-42 [11234874.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1248-55 [11230465.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1256-65 [11230466.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):583-8 [11304695.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):870-7 [11313175.001]
  • [Cites] Nat Med. 2001 Aug;7(8):961-6 [11479630.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2908-11 [11555609.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3251-7 [11595721.001]
  • [Cites] Chem Biol. 2001 Dec;8(12):1151-60 [11755394.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):75-85 [11801542.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):832-40 [12910529.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] Cancer. 1973 Jul;32(1):1-8 [4716773.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] Biochemistry. 1996 Oct 15;35(41):13303-9 [8873596.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):981-7 [9818072.001]
  • [Cites] J Med Chem. 1999 Jul 15;42(14):2493-7 [10411470.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):576-84 [15659504.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6780-4 [10841573.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1610-4 [16736024.001]
  • (PMID = 18927308.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006927; None / None / / P30 CA006927-46; United States / NCI NIH HHS / CA / P30 CA006927-46
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS113333; NLM/ PMC2777645
  •  go-up   go-down


5. Gholami S, Jacobs CD, Kapp DS, Parast LM, Norton JA: The value of surgery for retroperitoneal sarcoma. Sarcoma; 2009;2009:605840
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most were liposarcoma (44%) and high-grade (59%).
  • Thirty-eight patients had an initial complete resection; 15 (37%) developed recurrent sarcoma and 12 (80%) had a second complete resection.
  • Radiation therapy or chemotherapy had no significant impact on overall or recurrence-free survival.
  • Complete surgical resection is the treatment of choice for patients with initial and locally recurrent retroperitoneal sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):859-68 [8622034.001]
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] Curr Treat Options Oncol. 2000 Aug;1(3):274-8 [12057171.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):468-73 [12393986.001]
  • [Cites] Arch Surg. 2003 Mar;138(3):248-51 [12611567.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1 [14501502.001]
  • [Cites] Oncology. 2003;65 Suppl 2:80-4 [14586155.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):483-90 [15078637.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):669-75 [16003776.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):508-17 [16491338.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):234-8 [17081725.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):31-7 [19047280.001]
  • [Cites] Ann Surg. 1990 Jul;212(1):51-9 [2363604.001]
  • [Cites] Arch Surg. 1995 Oct;130(10):1104-9 [7575124.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):137-42 [19106689.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • (PMID = 19826633.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009337
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2760213
  •  go-up   go-down


6. Yoshida Y, Inoue K, Ohsako T, Nagamoto N, Tanaka E, Tsuruzoe S: [Weekly paclitaxel therapy is curative for patients with retroperitoneal liposarcoma]. Gan To Kagaku Ryoho; 2007 Mar;34(3):465-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Weekly paclitaxel therapy is curative for patients with retroperitoneal liposarcoma].
  • In March 2004, we resected a giant retroperitoneal liposarcoma and the transverse colon, spleen and left kidney in a 58-year-old woman.
  • In September 2004, computed tomography (CT) revealed multiple recurrences in the right lower abdomen, left upper abdomen, front of the left lobe of the liver, and at the back of the stomach.
  • In October 2004, we started mesna, doxorubicin, ifosfamide, and dacarbazine therapy (MAID); however, after 1 course, the disease progressed, and the patient developed edema in the bilateral legs due to inferior vena cava (IVC) compression.
  • In November 2004, we started weekly paclitaxel therapy (100 mg/m(2), once a week for 3 weeks followed by 1 drug-free week).
  • CT revealed no change as a result of chemotherapy; however, IVC compression had improved, and leg edema had decreased.
  • In August 2005, chemotherapy was stopped; therefore,the patient's condition worsened.
  • We performed weekly paclitaxel therapy for the patient with recurrent liposarcoma.
  • Therefore,we consider weekly paclitaxel therapy to be effective for liposarcoma treatment.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Liposarcoma / drug therapy. Paclitaxel / therapeutic use. Retroperitoneal Neoplasms / drug therapy
  • [MeSH-minor] Colectomy. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Middle Aged. Nephrectomy. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / secondary. Quality of Life. Spleen / surgery

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353645.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Goss G, Demetri G: Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care. Surg Oncol; 2000 Aug;9(2):53-9
Genetic Alliance. consumer health - Retroperitoneal liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care.
  • For patients with recurrent and unresectable liposarcoma, treating the sarcoma while maintaining quality of life becomes the major therapeutic goal.
  • Importantly, patients with advanced recurrent disease demonstrate the need for multidisciplinary team involvement, with timely consideration of palliative surgical, radiation therapy, and chemotherapy options.
  • In addition to the development of new cytotoxic agents, patients may be candidates for novel strategies such as differentiation therapies or anti-angiogenic approaches.
  • The recent explosion of knowledge regarding the cytogenetics, molecular, and cellular biology of liposarcomas allows us to remain positive that new translational therapies will be developed to improve the clinical outcomes of patients with these diseases.
  • [MeSH-major] Chromans / administration & dosage. Liposarcoma / drug therapy. Liposarcoma / surgery. Neoplasm Recurrence, Local / drug therapy. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / surgery. Thiazoles / administration & dosage. Thiazolidinediones
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094323.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Chromans; 0 / Thiazoles; 0 / Thiazolidinediones; I66ZZ0ZN0E / troglitazone
  • [Number-of-references] 26
  •  go-up   go-down


8. Michiels A, Hubens G, Ruppert M, Balliu L, Vaneerdeweg W: Giant liposarcoma of the stomach involving the mediastinum. Acta Chir Belg; 2007 Jul-Aug;107(4):468-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant liposarcoma of the stomach involving the mediastinum.
  • A case of a liposarcoma of the stomach in a 27-year old woman is described.
  • After surgical 'en-bloc' resection of the tumour, histopathologic examination yielded a diagnosis of pleiomorphic liposarcoma.
  • Because of the bad prognosis of this histologic type, the patient received adjuvant chemotherapy: a combination of doxorubicin and ifosfamide (MAI).
  • Palliative chemotherapy was started with the intent to prolong the young patient's life.
  • However 6 months later, the patient died of the recurrent disease.
  • Although liposarcoma is a very common soft tissue sarcoma, it is rarely seen in the stomach.
  • The standard therapy is surgical excision.
  • Over the last years, adjuvant therapy became more accepted.
  • Drugs of choice are doxorubicin and ifosfamide, although the benefits of this therapy are still largely unknown and doubtful.
  • [MeSH-major] Liposarcoma / pathology. Mediastinum / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966553.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


9. Gupta R, Sharma A, Arora R, Kulkarni MP, Chattopadhaya TK, Singh MK: Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist. J Gastrointest Cancer; 2010 Mar;41(1):79-83
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist.
  • BACKGROUND: Mesenteric liposarcoma is a rare intra-abdominal sarcoma with very few cases reported in the available English literature.
  • Incomplete resection of the tumor leads to recurrence, and recurrent tumors carry a risk of dedifferentiation.
  • Dedifferentiation in liposarcoma manifests as a nonlipogenic sarcoma, which is usually high-grade and may show osteosarcomatous differentiation rarely.
  • To the best of our knowledge, osteoid metaplasia in a well-differentiated liposarcoma without evidence of dedifferentiation has not been documented in the available literature.
  • CASE: We describe the case of a middle-aged adult man with a well-differentiated liposarcoma of the mesentery.
  • The patient presented with a recurrent tumor 5 years after the initial surgery.
  • At recurrence, the histological features were those of a well-differentiated liposarcoma with focal osseous metaplasia without any evidence of dedifferentiation in the extensive sections examined.
  • Such an occurrence in a recurrent well-differentiated liposarcoma is a perplexing problem due to the potential confusion with dedifferentiation.
  • This needs to be recognized to avoid overzealous chemotherapy and/or radiotherapy, which is required for dedifferentiated tumors.
  • [MeSH-major] Calcinosis / pathology. Liposarcoma / pathology. Mesentery / pathology. Neoplasm Recurrence, Local / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intern Med. 2007;46(7):373-5 [17409600.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1150-7 [7943536.001]
  • [Cites] World J Gastroenterol. 2007 Aug 14;13(30):4147-8 [17696239.001]
  • [Cites] Skeletal Radiol. 2003 May;32(5):286-9 [12679843.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):669-75 [16003776.001]
  • [Cites] Clin Neuropathol. 1996 Jan-Feb;15(1):60-2 [8998859.001]
  • [Cites] Jpn J Clin Oncol. 2006 Nov;36(11):735-8 [17000700.001]
  • [Cites] Semin Diagn Pathol. 2001 Nov;18(4):258-62 [11757865.001]
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):829-33 [8610559.001]
  • [Cites] Intern Med. 1998 Oct;37(10):884-90 [9840715.001]
  • [Cites] Surg Today. 1994;24(11):1003-6 [7772897.001]
  • (PMID = 20058101.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. May M, Seehafer M, Helke C, Gunia S, Hoschke B: [Liposarcoma of the spermatic cord--report of one new case and review of the literature]. Aktuelle Urol; 2004 Apr;35(2):130-3
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma of the spermatic cord--report of one new case and review of the literature].
  • [Transliterated title] Liposarkom des Samenstrangs--Darstellung eines Falls.
  • Liposarcoma of the spermatic cord is a rare entity.
  • Preferential treatment of spermatic cord liposarcoma is radical orchiectomy with high ligation of the cord.
  • Radiation therapy is recommended in addition to surgery in cases with evidence of more aggressive tumour behavior (i.e., high-grade tumour, lymphatic invasion, inadequate margin, or recurrence).
  • Pathological analysis demonstrated a well-differentiated liposarcoma with tumour detection in the surgical margin.
  • Without any postoperative adjuvant therapy in evidence of recurrence or metastasis was noted during the 12-month follow-up period.
  • Radical orchiectomy with wide local excision of the mass is the recommended therapy, while adjuvant radiotherapy may be considered in high-grade tumours and in recurrent liposarcomas.
  • Retroperitoneal lymphadenectomy does not offer any additional therapeutic benefit, and the role of chemotherapy is not well defined.
  • Regardless of initial therapy, the risk of local recurrence always necessitates long-term followup.
  • [MeSH-major] Genital Neoplasms, Male. Liposarcoma. Spermatic Cord
  • [MeSH-minor] Adult. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Orchiectomy. Radiotherapy, Adjuvant. Reoperation. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15146377.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Carter NJ, Keam SJ: Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs; 2010 Feb 12;70(3):355-76
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
  • It is indicated in the EU and many other countries for use in patients with advanced soft-tissue sarcoma (STS) who have progressed despite receiving previous treatment with anthracyclines and ifosfamide or in those who are unable to receive these agents.
  • It is also approved in the EU in combination with pegylated liposomal doxorubicin for the treatment of platinum-sensitive, recurrent ovarian cancer.
  • In addition, trabectedin holds orphan drug status for the treatment of advanced, recurrent STS in the US, Switzerland and Korea, and for the treatment of advanced, recurrent ovarian cancer in the US and Switzerland.
  • Clinical trials showed that intravenous trabectedin was effective in chemotherapy-experienced patients with advanced, recurrent liposarcoma or leiomyosarcoma, and results from a retrospective analysis suggest that the drug may be particularly effective in patients with advanced myxoid liposarcoma.
  • In addition, coadministration of trabectedin with pegylated liposomal doxorubicin was associated with a significantly longer progression-free survival (6 weeks) than pegylated liposomal doxorubicin monotherapy in patients with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy.
  • Results to date indicate that trabectedin is a valuable addition to the group of second-line antineoplastic agents available for the treatment of advanced, recurrent STS, and that it is a beneficial treatment for recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy when administered in conjunction with pegylated liposomal doxorubicin.
  • [MeSH-major] Antineoplastic Agents, Alkylating. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dioxoles. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tetrahydroisoquinolines

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4188-96 [19652065.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Dec;63(1):181-8 [18379785.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14 (20):6449-55 [18927284.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8155-62 [16912194.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10 ):1484-90 [16737808.001]
  • [Cites] Invest New Drugs. 2006 Jan;24(1):3-14 [16379042.001]
  • [Cites] Drugs. 2002;62(8):1185-92; discussion 1193-4 [12010079.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Apr 1;228(1):17-23 [18191164.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):449-57 [19190116.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23 (24):5484-92 [16110008.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):672-7 [15701855.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14 (20):6656-62 [18927308.001]
  • [Cites] Anticancer Drugs. 2005 Sep;16(8):811-5 [16096428.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12 ):2305-11 [14676811.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2964-71 [15805300.001]
  • [Cites] J Clin Oncol. 2010 Jul 1;28(19):3107-14 [20516432.001]
  • [Cites] Clin Pharmacol Ther. 2008 Jan;83(1):130-43 [17597713.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5902-8 [14522916.001]
  • [Cites] Mol Biol Cell. 2008 Sep;19(9):3969-81 [18632984.001]
  • [Cites] Am J Clin Dermatol. 2008;9(4):207-17 [18572972.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12 ):1618-24 [18000504.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jun;62(1):135-47 [17922277.001]
  • [Cites] Eur J Cancer. 1999 Nov;35(12):1705-10 [10674017.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12 ):3377-81 [12067978.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13062-7 [17656556.001]
  • [Cites] Drugs. 2007;67(15):2257-76 [17927287.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10 ):1802-9 [18497430.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):825-37 [16988825.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):609-18 [18243687.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19 [12357306.001]
  • [Cites] Invest New Drugs. 2010 Apr;28(2):145-55 [19238326.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):401-10 [17442231.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Dec;8(8):886-903 [19075571.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Eur J Cancer. 2008 Aug;44(12 ):1726-33 [18501589.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):565-7 [17613417.001]
  • [Cites] Ann Oncol. 2009 Nov;20(11):1794-802 [19556318.001]
  • [Cites] Eur J Cancer. 2009 Aug;45(12 ):2116-22 [19419856.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):576-84 [15659504.001]
  • [Cites] Curr Clin Pharmacol. 2009 Jan;4(1):38-42 [19149499.001]
  • [Cites] Br J Cancer. 2008 Sep 23;99 Suppl 1:S70-2 [18813266.001]
  • [Cites] Biochem Pharmacol. 2009 May 15;77(10 ):1642-54 [19426702.001]
  • [Cites] Clin Pharmacokinet. 2007;46(10 ):867-84 [17854236.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):347-53 [16721129.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1309-18 [18483318.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1867-74 [15774779.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1153-61 [19114300.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Ann Oncol. 2009 Aug;20(8):1439-44 [19465423.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):935-43 [16162970.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12 ):4725-32 [11156226.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii89-93 [18456783.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1920-6 [12932672.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Sep;6(8):766-94 [18926089.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1609-18 [18518789.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] Nat Prod Rep. 2009 Mar;26(3):322-37 [19240944.001]
  • [Cites] Nat Med. 2001 Aug;7(8):961-6 [11479630.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii14-6 [18456751.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2908-11 [11555609.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10 ):3251-7 [11595721.001]
  • (PMID = 20166769.001).
  • [ISSN] 1179-1950
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; ID0YZQ2TCP / trabectedin
  • [Number-of-references] 104
  •  go-up   go-down


12. Lahat G, Anaya DA, Wang X, Tuvin D, Lev D, Pollock RE: Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol; 2008 Jun;15(6):1585-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches.
  • BACKGROUND: Division of retroperitoneal liposarcoma (RPLS) into well-differentiated (WD) and dedifferentiated (DD) subtypes is established; however, WD and DD are usually treated similarly.
  • We hypothesized that WD and DD have distinct biological behaviors mandating different treatments.
  • METHODS: A prospective sarcoma database identified all primary/recurrent RPLS treated between 1996 and 2007: 77 DD (52%) and 58 WD (39.2%) patients were analyzed for recurrence rate, recurrence free survival (RFS), and overall survival (OS).
  • RESULTS: At presentation, WD were mostly primary whereas DD were mostly recurrent (75.9% versus 58.4%; p = 0.04).
  • A significant proportion of DD (37.7%) received chemotherapy compared to WD (1.7%; p < 0.0001).
  • Median time to recurrence was 55.5 months in WD versus 13.5 months in DD (p < 0.0001).
  • Treatment should therefore reflect these biologic differences by maximizing survivorship while avoiding unnecessarily extensive multivisceral resection.
  • [MeSH-major] Liposarcoma / pathology. Liposarcoma / surgery. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Jun;15(6):1555-6 [18347875.001]
  • (PMID = 18398663.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Lehnhardt M, Daigeler A, Homann HH, Hauser J, Langer S, Steinsträsser L, Soimaru C, Puls A, Steinau HU: [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases]. Chirurg; 2009 Apr;80(4):341-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases].
  • [Transliterated title] Die Bedeutung von Referenzzentren in Diagnose und Therapie von Weichgewebssarkomen der Extremitäten. Auswertung von 603 Fällen.
  • Correct histopathologic diagnosis is essential for adequate treatment of soft tissue sarcomas.
  • The records of 603 patients with soft tissue tumors of the extremities were reviewed concerning mismatches in primary and definite diagnoses relating to entity, evaluation of primary or recurrent tumor specimens, and the diagnosing pathology institution.
  • Liposarcoma and malignant fibrous histiocytoma were the most often diagnosed subgroups at 24% and 22.6%, respectively.
  • In the eight most frequent sarcoma types, malignant peripheral nerve sheath tumors and leiomyosarcoma had the highest rates of false primary diagnosis, 78.4% and 74.2% of cases, respectively.
  • For optimal treatment of soft tissue sarcomas, we suggest obtaining expert second opinion to ensure adequate surgical therapy and precise indications for radiation and chemotherapy.
  • [MeSH-major] Cancer Care Facilities. Extremities / surgery. Hospitals, Special. Hospitals, University. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diagnostic Errors. Female. Germany. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / diagnosis. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Neoplasm Staging. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery. Radiotherapy, Adjuvant. Referral and Consultation. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Cancer Treat Res. 2004;120:43-63 [15217217.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):404-6 [3179848.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):48-61 [9990113.001]
  • [Cites] Curr Top Pathol. 1995;89:123-51 [7882706.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):451-62 [15509479.001]
  • [Cites] Pathol Res Pract. 1988 Nov;183(6):698-705 [2851775.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):77-86 [15188669.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):212-9 [10613171.001]
  • [Cites] Bull Cancer. 2001 Aug;88(8):765-73 [11578945.001]
  • [Cites] Curr Oncol Rep. 2006 Jul;8(4):305-9 [17254531.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):111-5 [11823981.001]
  • [Cites] Chirurg. 2007 Jan;78(1):62-4 [16786340.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):157-67 [11856592.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):237-46 [15056054.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):329-35 [10989631.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • (PMID = 18523742.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, Sloan JA, Atherton P, Edmonson JH, Erlichman C, Randlev B, Wang Q, Freeman S, Rubin J: Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther; 2005 Mar;12(5):437-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.
  • We, therefore, undertook a phase I/II study of ONYX-015, days 1-5 every month administered intratumorally under radiographic guidance, in combination with MAP (mitomycin-C, doxorubicin, cisplatin) chemotherapy in patients with advanced sarcoma.
  • Sarcoma histologies were gastrointestinal stromal tumors (GIST, two patients), leiomyosarcoma (two patients), liposarcoma (one patient), and malignant peripheral nerve sheath tumor (1 patient).
  • Immunohistochemistry of the metastatic lesions prior to treatment showed that five out of six patients were positive for p53, while two patients also had mdm-2 overexpression.
  • ONYX-015 viral DNA was detected by quantitative PCR in the plasma of 5/6 patients on day 5 of the first cycle, and up to day 12 (7 days after the last viral dose) in one patient who had extended sampling for viral kinetics performed, suggesting viral replication in sarcoma tissue.
  • One patient with p53 mutation and MDM-2 amplification achieved a partial response to treatment that lasted 11 months.
  • In conclusion, intratumoral administration of ONYX-015 in combination with MAP chemotherapy is well tolerated with no significant toxicity due to ONYX-015 being encountered.
  • Detection of viral DNA in post treatment tumor specimens by ISH and detection of the ONYX-015 genome in the peripheral blood by quantitative PCR, up to 7 days after the last viral dose provide evidence for adenoviral replication.
  • Further investigation of this approach in patients with recurrent sarcomas is warranted.
  • [MeSH-major] Adenoviridae. Antineoplastic Agents / administration & dosage. Genetic Therapy / methods. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Viral / blood. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. DNA, Viral / analysis. DNA, Viral / blood. Doxorubicin / administration & dosage. Female. Humans. In Situ Hybridization. Injections, Intralesional. Male. Middle Aged. Mitomycin / administration & dosage. Viral Vaccines. Virus Replication

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15647767.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 84388; United States / NCI NIH HHS / CA / U01CA 69912
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antineoplastic Agents; 0 / DNA, Viral; 0 / ONYX015; 0 / Viral Vaccines; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; MAP protocol
  •  go-up   go-down


15. Pink D, Rahm J, Schoeler D, Schoenknecht TM, Reichardt P: Activity of paclitaxel in radiation induced and other secondary angiosarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):10578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10578 Background: Angiosarcomas (AS) represent 1-2% of adult soft tissue sarcomas and can arise anywhere in the body.
  • Major predisposing factors are therapeutic radiation and chronic lymphedema.
  • We report on a retrospectice single center experience with chemotherapy in 17 patients (pts.) with secondary angiosarcomas (SAS).
  • 12 female patients suffered from angiosarcoma of the breast/thoracic wall following operation and radiation + chemotherapy of a primary breast cancer with an interval of a median of 6 years (range 2-15 years).
  • 1 patient developed a SAS 6 years after resection and radiation of a liposarcoma in the limb.
  • RESULTS: 14/17 pts. received surgery as first treatment for SAS.
  • 10 pts. developed a locoregional recurrence, 1 pt. distant metastases.
  • All 14 patients with recurrent/metastatic disease were treated with chemotherapy.
  • 12 pts. received paclitaxel at a dose of 175 mg/m<sup>2</sup> q3w or 50-70 mg/m<sup>2</sup> q1w as first- or second-line therapy.
  • In only 3/11 cases, pts. responded to Anthracycline-based chemotherapy.
  • CONCLUSIONS: Paclitaxel shows high activity in SAS, comparable to the results in face and scalp angiosarcomas and can be considered a standard treatment option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963758.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Carter NJ, Keam SJ: Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs; 2007;67(15):2257-76
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
  • Intravenous trabectedin administered once every 3 weeks is approved as monotherapy in Europe for use in patients with advanced soft tissue sarcoma (STS) after failure of standard therapy with anthracyclines or ifosfamide, or who are unsuited to receive these agents.
  • It also has orphan drug status in STS in the US and in ovarian cancer in the US and Europe, and is under investigation as combination therapy in patients with recurrent ovarian cancer.
  • In clinical trials, trabectedin showed efficacy in the treatment of patients with advanced or metastatic STS, especially those with leiomyosarcoma or liposarcoma, as well as in women with platinum-sensitive advanced or recurrent ovarian cancer.
  • The introduction of trabectedin expands the currently limited range of effective treatment options for patients with advanced or metastatic STS; trabectedin also has the potential to be a beneficial treatment for advanced or recurrent ovarian cancer.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / therapeutic use. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tetrahydroisoquinolines / therapeutic use

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1998 Sep;9(9):981-7 [9818072.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):333-42 [15713904.001]
  • [Cites] J Med Chem. 2006 Nov 16;49(23 ):6925-9 [17154523.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8155-62 [16912194.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10 ):1484-90 [16737808.001]
  • [Cites] Invest New Drugs. 2006 Jan;24(1):3-14 [16379042.001]
  • [Cites] Drugs. 2002;62(8):1185-92; discussion 1193-4 [12010079.001]
  • [Cites] Biochem Pharmacol. 2003 Dec 15;66(12 ):2381-95 [14637196.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23 (24):5484-92 [16110008.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):323-33 [15661559.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):672-7 [15701855.001]
  • [Cites] Anticancer Drugs. 2005 Sep;16(8):811-5 [16096428.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12 ):2305-11 [14676811.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2964-71 [15805300.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5902-8 [14522916.001]
  • [Cites] Mol Pharmacol. 2005 Nov;68(5):1496-503 [15961672.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12 ):3893-903 [12473605.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1327-31 [15177491.001]
  • [Cites] Ann Oncol. 2007 Apr;18 Suppl 2:ii74-6 [17491057.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12 ):3377-81 [12067978.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):1-7 [16633714.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 2):S1-15 [17512352.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):825-37 [16988825.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19 [12357306.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Clin Cancer Res. 2010 May 1;16(9):2656-65 [20406837.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1610-4 [16736024.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6 [16716798.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):1-20 [17291226.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):576-84 [15659504.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1605-16 [16273217.001]
  • [Cites] Ann Oncol. 2007 Apr;18 Suppl 2:ii12-4 [17491026.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):347-53 [16721129.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1867-74 [15774779.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):336-40 [17545796.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):935-43 [16162970.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12 ):4725-32 [11156226.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1920-6 [12932672.001]
  • [Cites] Cancer. 2003 Aug 15;98 (4):832-40 [12910529.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] Lancet. 2003 Jun 21;361(9375):2099-106 [12826431.001]
  • [Cites] Orthop Nurs. 2007 Jan-Feb;26(1):4-11; quiz 12-3 [17273099.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2908-11 [11555609.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10 ):3251-7 [11595721.001]
  • (PMID = 17927287.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; ID0YZQ2TCP / trabectedin
  • [Number-of-references] 80
  •  go-up   go-down


17. Blanchard DK, Reynolds CA, Grant CS, Donohue JH: Primary nonphylloides breast sarcomas. Am J Surg; 2003 Oct;186(4):359-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to examine the presentation, treatment, and prognosis of patients presenting with these neoplasms.
  • RESULTS: Of the 55 patients, 17 had breast-conserving therapy and 38 women had mastectomy.
  • The types of sarcoma included angiosarcoma (18), malignant fibrous histiocytoma (11), stromal sarcoma (8), liposarcoma (4), leiomyosarcoma (4), dermatofibrosarcoma protuberans (4), osteosarcoma (3), fibrosarcoma (2), and rhabdomyosarcoma (1).
  • Twenty-nine of 53 patients (55%) developed recurrent sarcoma, and 23 patients (43%) died of their disease.
  • Of 34 patients who did not receive adjuvant chemotherapy or radiation, 13 died of their disease (38%), as compared with 10 of 16 patients (63%) who did receive adjuvant therapy.
  • CONCLUSIONS: While primary nonphylloides breast sarcomas are rare tumors, their treatment and prognosis are poor.
  • Adjuvant chemotherapy and radiation did not improve survival in this report.
  • Surgical extirpation remains the only effective treatment.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14553850.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Issakov J, Merimsky O, Gutman M, Kollender Y, Lev-Chelouche D, Abu-Abid S, Lifschitz-Mercer B, Inbar M, Klausner JM, Meller I: Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations. Ann Surg Oncol; 2000 Mar;7(2):155-9
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
  • BACKGROUND: Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan was used as induction treatment in locally advanced extremity soft-tissue sarcomas for limb sparing surgery.
  • METHODS: Fresh tumor specimens of 27 high grade extensive soft-tissue sarcomas and 3 recurrent desmoid tumors of the extremities were collected 6 to 8 weeks after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha plus melphalan.
  • The specimens were studied for surgical margins, extent and type of tumor necrosis, lymph node involvement, perineural and vascular invasion, and the effects on adjacent normal tissues such as nerves, muscles, and blood vessels.
  • Some nonspecific changes were noted in the soft tissues around the mass.
  • The responsive types were malignant fibrous histiocytoma, followed by myxoid liposarcoma and synovial sarcoma.
  • The soft tissues adjacent to the tumor bed did not show major morphological changes.
  • No correlation was found between the histological changes and each of the following: the anatomical (upper vs. lower limb) or compartmental location of the tumor; whether the tumor was primary or recurrent; and the types of previous treatment (systemic chemotherapy or radiotherapy) and tumor size.
  • CONCLUSIONS: This is the first serial histological description of the effects of tumor necrosis factor-alpha and melphalan administered via hyperthermic isolated limb perfusion on the tumoral masses of limb soft-tissue sarcomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Melphalan / administration & dosage. Sarcoma / pathology. Soft Tissue Neoplasms / pathology. Tumor Necrosis Factor-alpha / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761796.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


19. Daryanani D, de Vries EG, Guchelaar HJ, van Weerden TW, Hoekstra HJ: Hyperthermic isolated regional perfusion of the limb with carboplatin. Eur J Surg Oncol; 2000 Dec;26(8):792-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To investigate the feasibility of hyperthermic isolated regional perfusion (HIRP) with carboplatin in the management of locally recurrent and/or intransit metastases of melanoma or locally advanced soft tissue sarcoma.
  • METHODS: Three patients, two with locally advanced melanoma and one with a low-grade liposarcoma of the lower extremity, were treated with HIRP under mild hyperthermia (39-40 degrees C) with 125 mg carboplatin/l perfused limb volume.
  • The two melanoma patients showed a complete response but developed local recurrences within 1.5 years after perfusion.
  • One of the melanoma patients and the sarcoma patient died from lung metastases 56 and 31 months post-perfusion treatment, respectively.
  • The other melanoma patient is alive 95+ months post-perfusion treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Melanoma / drug therapy. Melanoma / secondary. Sarcoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11087648.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


20. Candela G, Di Libero L, Varriale S, Manetta F, Giordano M, Lanza M, Argenziano G, Pizza A, Sciascia V, Napolitano S, Riccio M, Esposito D, Santini L: [Diagnostic and therapeutic guidelines for entero-cutaneous fistulas. Personal experience and literature review]. Minerva Chir; 2007 Aug;62(4):293-303

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic and therapeutic guidelines for entero-cutaneous fistulas. Personal experience and literature review].
  • They can occur spontaneously, or after an injury or a surgical procedure.
  • The experience reported here is about three ECF cases occurred after surgery and treated only with medical therapy.
  • The first case is a woman in good general conditions who underwent surgery to remove a recurrent retroperitoneal myxoid liposarcoma situated in the right lower quadrant.
  • The other two patients analyzed were affected by sepsis and metabolic unbalance and had developed a fistula after colonic resection.
  • Fluids and electrolytes adjustments and sepsis management have preceded any other kind of therapy.
  • In order to heal and protect peri-fistula skin we have used sterile washing solutions, absorbable ionic exchange resin, silver and polyurethanes based medications and colostomy bags adhesive systems.
  • Since surgical treatment of ECF is associated with high rates of morbidity and mortality, conservative treatment should always be taken into consideration.
  • When conservative treatment fails, delayed surgical intervention has been related to a higher rate of success.
  • The purpose of this study is to describe diagnostic and therapeutic guidelines to general surgeons, like ourselves, whenever they have to deal with ECF cases.
  • [MeSH-major] Colostomy. Intestinal Fistula / diagnosis. Intestinal Fistula / drug therapy
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Antidiarrheals / therapeutic use. Disinfectants. Drug Therapy, Combination. Female. Hormones / therapeutic use. Humans. Loperamide / therapeutic use. Male. Middle Aged. Myxosarcoma / surgery. Polyurethanes. Practice Guidelines as Topic. Proton Pump Inhibitors. Retroperitoneal Neoplasms / surgery. Risk Factors. Sepsis / complications. Sepsis / therapy. Somatostatin / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641589.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antidiarrheals; 0 / Disinfectants; 0 / Hormones; 0 / Polyurethanes; 0 / Proton Pump Inhibitors; 51110-01-1 / Somatostatin; 6X9OC3H4II / Loperamide
  • [Number-of-references] 47
  •  go-up   go-down






Advertisement